Company Provides Full Year and First Quarter
2020 Guidance
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced
financial results for the fourth quarter and year ended December
31, 2019, that were in line with the Company’s previously issued
guidance. Revenue was $780.2 million for the fourth quarter, up
4.9% from $743.5 million for the fourth quarter of 2018. Net loss
attributable to Acadia stockholders for the fourth quarter of 2019
was $11.3 million, or $0.13 per diluted share, compared with a net
loss of $331.6 million, or $3.80 per diluted share, for the fourth
quarter of 2018.
For the fourth quarter, Acadia’s total same facility revenue
increased 4.5% compared with the fourth quarter of 2018, including
a 0.4% increase in patient days and a 4.1% increase in revenue per
patient day. Total same facility EBITDA margin increased 20 basis
points to 22.0%. U.S. same facility revenue increased 5.5%,
including a 2.4% increase in patient days and a 3.0% increase in
revenue per patient day. U.S. same facility EBITDA margin increased
30 basis points to 25.0%. For the U.K. operations, same facility
revenue was up 2.7% for the fourth quarter of 2019 from the fourth
quarter last year, reflecting a 4.7% increase in revenue per
patient day offset by a 2.0% decrease in patient days. U.K. same
facility EBITDA margin declined 40 basis points to 16.1%. Acadia’s
consolidated adjusted EBITDA for the fourth quarter of 2019 was
$144.4 million, compared with $133.9 million for the fourth quarter
of 2018.
Results for the fourth quarter of 2019 include
transaction-related expenses of $11.8 million, an impairment charge
of $54.4 million, which relates to a non-cash impairment of
property and equipment at certain closed facilities, and the income
tax effect of adjustments to income of $9.9 million based on a tax
rate of 18.1%. Adjusted income attributable to Acadia stockholders
per diluted share was $0.51 for the fourth quarter of 2019.
A reconciliation of all non-GAAP financial results in this press
release appears beginning on page 8.
Debbie Osteen, Chief Executive Officer of Acadia Healthcare
Company, remarked, “Results for this quarter were in line with our
expectations. Our U.S. facilities showed improvement across key
metrics, as we continued to address and resolve certain facility
issues that affected our results in the third quarter. Our U.K.
facilities continue to see stability in their operating trends.
“During the fourth quarter, we added 171 beds to Acadia’s
operations, including 150 beds in our U.S. operations and 21 beds
in the U.K. For the full year, we added 585 beds to existing and
new facilities, including 519 beds in the U.S. Moving forward to
2020, we expect to add approximately 600 beds in the U.S. We are
excited about the opportunities ahead for Acadia to extend our
market reach and advance our position as a leading operator of
behavioral healthcare facilities.
“We launched a formal process regarding the sale of our U.K.
business in January 2020, following the U.K. elections and
preliminary discussions with prospective buyers at the end of last
year. Consistent with market practice for U.K. transactions of this
nature, and in conjunction with our advisors, we solicited and now
have received initial, non-binding offers to acquire our U.K.
business from multiple bidders. We are currently in the second
phase of the sale process, during which interested bidders will
receive proposed transaction documents and complete their
confirmatory due diligence. We will continue to work with our
financial and legal advisors and will update the market when and as
we determine it is appropriate,” added Osteen.
Acadia today established its financial guidance for the full
year 2020, as follows:
- Revenue in a range of $3.28 billion to $3.34 billion;
- Adjusted EBITDA in a range of $610 million to $630
million;
- Adjusted earnings per diluted share in a range of $2.20 to
$2.40;
- Stock compensation expense of approximately $22 million;
- Depreciation & amortization expense in a range of $175
million to $180 million;
- Interest expense in a range of $172 million to $177
million;
- Total weighted average shares outstanding (diluted) of
approximately 88.1 million;
- Operating cash flows in a range of $375 million to $410
million;
- Total capital expenditures in a range of $330 million to $350
million, including approximately $90 million for maintenance
capital expenditures;
- An exchange rate of $1.30 per British Pound Sterling; and
- A tax rate of approximately 17%.
Acadia also established its financial guidance for the first
quarter of 2020, as follows:
- Revenue in a range of $795 million to $805 million;
- Adjusted EBITDA in a range of $133 million to $137 million;
and
- Adjusted earnings per diluted share in a range of $0.37 to
$0.42.
The Company’s guidance does not include the impact of any future
acquisitions, divestitures or transaction-related expenses.
Osteen concluded, “We expect to see continued improvement and
high single-digit revenue growth and EBITDA margin improvement in
the second half of 2020 for our U.S. facilities. Our first quarter
guidance reflects the ongoing progress we continue to realize
regarding the implementation of our facility improvement plans,
operational improvement initiatives and numerous growth
initiatives. With respect to our operational improvement
initiatives, we believe we will achieve approximately $20 million
in annualized cost savings by the end of 2020, which is in line
with our original announcement in May of last year. We are pleased
with our progress to date and look forward to realizing the
incremental benefits of our strategy while we continue to support
our patients with the highest quality of care. In the U.K., we
anticipate our revenue growth will be driven by re-tooled beds
coming back online and improved occupancy trends.”
EBITDA is defined as net (loss) income adjusted for net income
attributable to noncontrolling interests, provision for (benefit
from) income taxes, net interest expense and depreciation and
amortization. Adjusted EBITDA is defined as EBITDA adjusted for
equity-based compensation expense, transaction-related expenses,
debt extinguishment costs, legal settlements expense and loss on
impairment. Adjusted income is defined as net (loss) income
adjusted for transaction-related expenses, tax reform impact, debt
extinguishment costs, legal settlements expense, loss on impairment
and income tax effect of adjustments to income.
Acadia will hold a conference call to discuss its fourth quarter
financial results at 9:00 a.m. Eastern Time on Friday, February 28,
2020. A live webcast of the conference call will be available at
www.acadiahealthcare.com in the “Investors” section of the website.
The webcast of the conference call will be available through March
14, 2020.
Risk Factors
This news release contains forward-looking statements.
Generally, words such as “may,” “will,” “should,” “could,”
“anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue,”
and “believe” or the negative of or other variation on these and
other similar expressions identify forward-looking statements.
These forward-looking statements are made only as of the date of
this news release. We do not undertake to update or revise the
forward-looking statements, whether as a result of new information,
future events or otherwise. Forward-looking statements are based on
current expectations and involve risks and uncertainties and our
future results could differ significantly from those expressed or
implied by our forward-looking statements. Factors that may cause
actual results to differ materially include, without limitation,
(i) potential difficulties operating our business in light of
political and economic instability in the U.K. and globally
relating to the U.K.’s departure from the European Union; (ii) the
impact of fluctuations in foreign exchange rates, including the
devaluation of the British Pound Sterling (GBP) relative to the
U.S. Dollar (USD); (iii) Acadia’s efforts to sell its U.K.
operations may not result in any definitive transaction or enhance
stockholder value; (iv) potential difficulties in successfully
integrating the operations of acquired facilities or realizing the
expected benefits and synergies of our acquisitions, joint ventures
and de novo transactions; (v) Acadia’s ability to add beds, expand
services, enhance marketing programs and improve efficiencies at
its facilities; (vi) potential reductions in payments received by
Acadia from government and fourth-party payors; (vii) the
occurrence of patient incidents, governmental investigations and
adverse regulatory actions, which could adversely affect the price
of our common stock and result in substantial payments and
incremental regulatory burdens; (viii) the risk that Acadia may not
generate sufficient cash from operations to service its debt and
meet its working capital and capital expenditure requirements; and
(ix) potential operating difficulties, labor costs, client
preferences, changes in competition and general economic or
industry conditions that may prevent Acadia from realizing the
expected benefits of its business strategies. These factors and
others are more fully described in Acadia’s periodic reports and
other filings with the SEC.
About Acadia
Acadia is a provider of behavioral healthcare services. At
December 31, 2019, Acadia operated a network of 585 behavioral
healthcare facilities with approximately 18,200 beds in 40 states,
the United Kingdom and Puerto Rico. Acadia provides behavioral
health and addiction services to its patients in a variety of
settings, including inpatient psychiatric hospitals, specialty
treatment facilities, residential treatment centers and outpatient
clinics.
Acadia Healthcare Company, Inc. Condensed
Consolidated Statements of Operations (Unaudited)
Three Months Ended December
31,
Year Ended December
31,
2019
2018
2019
2018
(In thousands, except per share amounts)
Revenue
$
780,232
$
743,547
$
3,107,462
$
3,012,442
Salaries, wages and benefits (including equity-based
compensation expense of $2,985, $2,728, $17,307 and $22,001,
respectively)
428,781
413,162
1,717,180
1,659,348
Professional fees
63,395
60,437
240,983
227,425
Supplies
31,400
30,356
123,061
119,314
Rents and leases
21,369
19,892
82,229
80,282
Other operating expenses
93,916
88,521
375,433
354,498
Depreciation and amortization
41,767
39,472
164,044
158,832
Interest expense, net
43,710
47,704
187,094
185,410
Debt extinguishment costs
-
875
-
1,815
Legal settlements expense
-
22,076
-
22,076
Loss on impairment
54,386
337,889
54,386
337,889
Transaction-related expenses
11,756
24,499
27,064
34,507
Total expenses
790,480
1,084,883
2,971,474
3,181,396
(Loss) income before income taxes
(10,248
)
(341,336
)
135,988
(168,954
)
Provision for (benefit from) income taxes
65
(9,807
)
25,866
6,532
Net (loss) income
(10,313
)
(331,529
)
110,122
(175,486
)
Net income attributable to noncontrolling interests
(941
)
(108
)
(1,199
)
(264
)
Net (loss) income attributable to Acadia Healthcare Company, Inc.
$
(11,254
)
$
(331,637
)
$
108,923
$
(175,750
)
Earnings per share attributable to Acadia Healthcare
Company, Inc. stockholders: Basic
$
(0.13
)
$
(3.80
)
$
1.24
$
(2.01
)
Diluted
$
(0.13
)
$
(3.80
)
$
1.24
$
(2.01
)
Weighted-average shares outstanding: Basic
87,674
87,382
87,612
87,288
Diluted
87,674
87,382
87,816
87,288
Acadia Healthcare Company, Inc. Condensed Consolidated
Balance Sheets (Unaudited)
December 31,
2019
2018
(In thousands) ASSETS Current assets: Cash and
cash equivalents
$
124,192
$
50,510
Accounts receivable, net
339,775
318,087
Other current assets
78,244
81,820
Total current assets
542,211
450,417
Property and equipment, net
3,224,034
3,107,766
Goodwill
2,449,131
2,396,412
Intangible assets, net
90,357
88,990
Deferred tax assets
3,339
3,468
Derivative instrument assets
-
60,524
Operating lease right-of-use assets
501,837
-
Other assets
68,233
64,927
Total assets
$
6,879,142
$
6,172,504
LIABILITIES AND EQUITY Current liabilities:
Current portion of long-term debt
$
43,679
$
34,112
Accounts payable
127,045
117,740
Accrued salaries and benefits
122,552
113,299
Current portion of operating lease liabilities
29,140
-
Other accrued liabilities
141,160
151,226
Total current liabilities
463,576
416,377
Long-term debt
3,105,420
3,159,375
Deferred tax liabilities
71,860
80,372
Operating lease liabilities
502,252
-
Derivative instrument liabilities
68,915
-
Other liabilities
128,587
154,267
Total liabilities
4,340,610
3,810,391
Redeemable noncontrolling interests
33,151
28,806
Equity: Common stock
877
874
Additional paid-in capital
2,557,642
2,541,987
Accumulated other comprehensive loss
(414,884
)
(462,377
)
Retained earnings
361,746
252,823
Total equity
2,505,381
2,333,307
Total liabilities and equity
$
6,879,142
$
6,172,504
Acadia Healthcare Company, Inc. Condensed Consolidated
Statements of Cash Flows (Unaudited)
Year Ended December
31,
2019
2018
(In thousands) Operating activities:
Net income (loss)
$
110,122
$
(175,486
)
Adjustments to reconcile net income (loss) to net cash provided
by continuing operating activities: Depreciation and
amortization
164,044
158,832
Amortization of debt issuance costs
11,987
10,456
Equity-based compensation expense
17,307
22,001
Deferred income taxes
1,780
(9,714
)
Debt extinguishment costs
-
1,815
Legal settlements expense
-
22,076
Loss on impairment
54,386
337,889
Other
4,035
12,371
Change in operating assets and liabilities: Accounts
receivable, net
(19,060
)
(16,821
)
Other current assets
(1,344
)
13,864
Other assets
(73
)
2,762
Accounts payable and other accrued liabilities
(21,354
)
26,054
Accrued salaries and benefits
7,820
15,748
Other liabilities
3,254
(5,219
)
Net cash provided by continuing operating activities
332,904
416,628
Net cash used in discontinued operating activities
-
(2,548
)
Net cash provided by operating activities
332,904
414,080
Investing activities: Cash paid for
acquisitions, net of cash acquired
(45,677
)
-
Cash paid for capital expenditures
(284,682
)
(341,462
)
Cash paid for real estate acquisitions
(7,618
)
(18,383
)
Settlement of foreign currency derivatives
105,008
-
Proceeds from sale of property and equipment
18,076
8,248
Other
13,752
(9,367
)
Net cash used in investing activities
(201,141
)
(360,964
)
Financing activities: Borrowings on
revolving credit facility
76,573
-
Principal payments on revolving credit facility
(76,573
)
-
Principal payments on long-term debt
(52,984
)
(39,738
)
Repayment of long-term debt
-
(21,920
)
Common stock withheld for minimum statutory taxes, net
(1,649
)
(3,407
)
Distributions to noncontrolling interests
(154
)
-
Other
(6,840
)
(2,265
)
Net cash used in financing activities
(61,627
)
(67,330
)
Effect of exchange rate changes on cash
3,546
(2,566
)
Net increase (decrease) in cash and cash equivalents
73,682
(16,780
)
Cash and cash equivalents at beginning of the period
50,510
67,290
Cash and cash equivalents at end of the period
$
124,192
$
50,510
Effect of acquisitions: Assets
acquired, excluding cash
$
49,715
$
-
Liabilities assumed
(4,038
)
-
Cash paid for acquisitions, net of cash acquired
$
45,677
$
-
Acadia Healthcare Company, Inc. Operating Statistics
(Unaudited, Revenue in thousands)
Three Months Ended December
31,
Year Ended December
31,
2019
2018
% Change
2019
2018
% Change
Same Facility Results (a,c) Revenue
$
742,391
$
710,304
4.5%
$
2,957,051
$
2,813,676
5.1%
Patient Days
1,133,208
1,128,348
0.4%
4,547,523
4,480,163
1.5%
Admissions
42,977
42,372
1.4%
176,120
169,835
3.7%
Average Length of Stay (b)
26.4
26.6
-1.0%
25.8
26.4
-2.1%
Revenue per Patient Day
$
655
$
630
4.1%
$
650
$
628
3.5%
EBITDA margin
22.0
%
21.8
%
20 bps
23.1
%
23.9
%
-80 bps U.S. Same Facility Results (a) Revenue
$
488,112
$
462,601
5.5%
$
1,955,730
$
1,849,058
5.8%
Patient Days
635,929
620,977
2.4%
2,546,768
2,467,725
3.2%
Admissions
40,712
40,101
1.5%
166,774
160,310
4.0%
Average Length of Stay (b)
15.6
15.5
0.9%
15.3
15.4
-0.8%
Revenue per Patient Day
$
768
$
745
3.0%
$
768
$
749
2.5%
EBITDA margin
25.0
%
24.7
%
30 bps
26.3
%
26.6
%
-30 bps U.K. Same Facility Results (a,c) Revenue
$
254,279
$
247,703
2.7%
$
1,001,321
$
964,618
3.8%
Patient Days
497,279
507,371
-2.0%
2,000,755
2,012,438
-0.6%
Admissions
2,265
2,271
-0.3%
9,346
9,525
-1.9%
Average Length of Stay (b)
219.5
223.4
-1.7%
214.1
211.3
1.3%
Revenue per Patient Day
$
511
$
488
4.7%
$
500
$
479
4.4%
EBITDA margin
16.1
%
16.5
%
-40 bps
16.7
%
18.9
%
-220 bps U.S. Facility Results Revenue
$
501,225
$
472,194
6.1%
$
2,008,381
$
1,904,695
5.4%
Patient Days
652,415
639,687
2.0%
2,613,164
2,538,737
2.9%
Admissions
42,222
40,322
4.7%
172,320
161,387
6.8%
Average Length of Stay (b)
15.5
15.9
-2.6%
15.2
15.7
-3.6%
Revenue per Patient Day
$
768
$
738
4.1%
$
769
$
750
2.4%
EBITDA margin
24.3
%
23.8
%
50 bps
25.1
%
25.6
%
-50 bps U.K. Facility Results (c) Revenue
$
279,007
$
271,630
2.7%
$
1,099,081
$
1,059,733
3.7%
Patient Days
664,709
678,162
-2.0%
2,673,715
2,702,551
-1.1%
Admissions
2,626
2,550
3.0%
10,786
10,776
0.1%
Average Length of Stay (b)
253.1
265.9
-4.8%
247.9
250.8
-1.2%
Revenue per Patient Day
$
420
$
401
4.8%
$
411
$
392
4.8%
EBITDA margin
14.4
%
14.6
%
-20 bps
15.2
%
16.7
%
-150 bps Total Facility Results (c) Revenue
$
780,232
$
743,824
4.9%
$
3,107,462
$
2,964,428
4.8%
Patient Days
1,317,124
1,317,849
-0.1%
5,286,879
5,241,288
0.9%
Admissions
44,848
42,872
4.6%
183,106
172,163
6.4%
Average Length of Stay (b)
29.4
30.7
-4.5%
28.9
30.4
-5.2%
Revenue per Patient Day
$
592
$
564
5.0%
$
588
$
566
3.9%
EBITDA margin
20.8
%
20.5
%
30 bps
21.6
%
22.5
%
-90 bps (a) Results for the periods presented exclude the
elderly care division of our U.K. operations and certain closed
services. (b) Average length of stay is defined as patient days
divided by admissions. (c) Revenue and revenue per patient day for
the three months and year ended December 31, 2018 is adjusted to
reflect the foreign currency exchange rate for the comparable
periods of 2019 in order to eliminate the effect of changes in the
exchange rate. The exchange rate used in the adjusted revenue and
revenue per patient day amounts for the three months and year ended
December 31, 2018 is 1.29 and 1.28, respectively.
Acadia
Healthcare Company, Inc. Reconciliation of Net Income
Attributable to Acadia Healthcare Company, Inc. to Adjusted
EBITDA (Unaudited)
Three Months Ended December
31,
Year Ended December
31,
2019
2018
2019
2018
(in thousands) Net (loss) income attributable to
Acadia Healthcare Company, Inc.
$
(11,254
)
$
(331,637
)
$
108,923
$
(175,750
)
Net income attributable to noncontrolling interests
941
108
1,199
264
Provision for (benefit from) income taxes
65
(9,807
)
25,866
6,532
Interest expense, net
43,710
47,704
187,094
185,410
Depreciation and amortization
41,767
39,472
164,044
158,832
EBITDA
75,229
(254,160
)
487,126
175,288
Adjustments: Equity-based compensation expense (a)
2,985
2,728
17,307
22,001
Transaction-related expenses (b)
11,756
24,499
27,064
34,507
Debt extinguishment costs (c)
-
875
-
1,815
Legal settlements expense (d)
-
22,076
-
22,076
Loss on impairment (e)
54,386
337,889
54,386
337,889
Adjusted EBITDA
$
144,356
$
133,907
$
585,883
$
593,576
See footnotes on page 10.
Acadia Healthcare Company,
Inc. Reconciliation of Adjusted Income Attributable to
Acadia Healthcare Company, Inc. to Net Income Attributable
to Acadia Healthcare Company, Inc. (Unaudited)
Three Months Ended December
31,
Year Ended December
31,
2019
2018
2019
2018
(in thousands, except per share amounts) Net (loss)
income attributable to Acadia Healthcare Company, Inc.
$
(11,254
)
$
(331,637
)
$
108,923
$
(175,750
)
Adjustments to income: Transaction-related expenses (b)
11,756
24,499
27,064
34,507
Tax reform impact (f)
-
-
-
(10,472
)
Debt extinguishment costs (c)
-
875
-
1,815
Legal settlements expense (d)
-
22,076
-
22,076
Loss on impairment (e)
54,386
337,889
54,386
337,889
Income tax effect of adjustments to income (g)
(9,860
)
(12,866
)
(11,244
)
(14,687
)
Adjusted income attributable to Acadia Healthcare Company, Inc.
$
45,028
$
40,836
$
179,129
$
195,378
Weighted-average shares outstanding - diluted (h)
87,963
87,508
87,816
87,415
Adjusted income attributable to Acadia Healthcare Company,
Inc. per diluted share
$
0.51
$
0.47
$
2.04
$
2.24
See footnotes on page 10.
Acadia Healthcare Company, Inc.
Footnotes
We have included certain financial measures in this press
release, including EBITDA, Adjusted EBITDA, and Adjusted income,
which are “non-GAAP financial measures” as defined under the rules
and regulations promulgated by the SEC. We define EBITDA as net
income adjusted for net income (loss) attributable to
noncontrolling interests, provision for (benefit from) income
taxes, net interest expense and depreciation and amortization. We
define Adjusted EBITDA as EBITDA adjusted for equity-based
compensation expense, transaction-related expenses, debt
extinguishment costs, legal settlements expense and loss on
impairment. We define Adjusted income as net income (loss) adjusted
for transaction-related expenses, tax reform impact, debt
extinguishment costs, legal settlements expense, loss on impairment
and income tax effect of adjustments to income.
EBITDA, Adjusted EBITDA, and Adjusted income are supplemental
measures of our performance and are not required by, or presented
in accordance with, generally accepted accounting principles in the
United States (“GAAP”). EBITDA, Adjusted EBITDA, and Adjusted
income are not measures of our financial performance under GAAP and
should not be considered as alternatives to net income or any other
performance measures derived in accordance with GAAP or as an
alternative to cash flow from operating activities as measures of
our liquidity. Our measurements of EBITDA, Adjusted EBITDA, and
Adjusted income may not be comparable to similarly titled measures
of other companies. We have included information concerning EBITDA,
Adjusted EBITDA, and Adjusted income in this press release because
we believe that such information is used by certain investors as
measures of a company’s historical performance. We believe these
measures are frequently used by securities analysts, investors and
other interested parties in the evaluation of issuers of equity
securities, many of which present EBITDA, Adjusted EBITDA, and
Adjusted income when reporting their results. Our presentation of
EBITDA, Adjusted EBITDA, and Adjusted income should not be
construed as an inference that our future results will be
unaffected by unusual or nonrecurring items.
The Company is not able to provide a reconciliation of projected
Adjusted EBITDA and adjusted earnings per diluted share, where
provided, to expected results due to the unknown effect, timing and
potential significance of transaction-related expenses and the tax
effect of such expenses.
(a) Represents the equity-based compensation expense of
Acadia.
(b) Represents transaction-related expenses incurred by Acadia
primarily related to termination, restructuring, strategic review
and other acquisition-related costs.
(c) Represents debt extinguishment costs recorded in connection
with the repricing amendments to the Amended and Restated Credit
Agreement in March 2018 and the repayment of the 9.0% and 9.5%
Revenue Bonds in December 2018.
(d) Represents $19.0 million related to the Company’s billing
for lab services in West Virginia and $3.1 million related to the
resolution of the shareholder class action lawsuit in 2011 in
connection with our merger with PHC.
(e) For the three months and year ended December 31, 2019,
represents a non-cash long-lived asset impairment charge of $27.2
million related to two closed U.S. facilities and $27.2 million
related to certain closed U.K. facilities. For the three months and
year ended December 31, 2018, represents a non-cash goodwill
impairment charge of $325.9 million and a non-cash long-lived asset
impairment charge of $12.0 million related to certain U.K.
facilities.
(f) Represents tax benefit related to the enactment of the Tax
Cuts and Jobs Act.
(g) Represents the income tax effect of adjustments to income
based on tax rates of 18.1% and 7.0% for the three months ended
December 31, 2019 and 2018, respectively, and 17.2% and 14.0% for
the year ended December 31, 2019 and 2018, respectively.
(h) For the three months ended December 31, 2019 and three
months and year ended December 31, 2018, approximately 0.2 million,
0.1 million and 0.1 million, respectively, of the outstanding
restricted stock and shares of common stock issuable upon exercise
of outstanding stock option awards have been included in the
calculation of weighted-average shares outstanding-diluted. These
shares are excluded from the calculation of diluted earnings per
share in the condensed consolidated statement of operations because
the net loss for the respective periods cause such securities to be
anti-dilutive.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200227005895/en/
Gretchen Hommrich Director, Investor Relations (615)
861-6000
Acadia Healthcare (NASDAQ:ACHC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acadia Healthcare (NASDAQ:ACHC)
Historical Stock Chart
From Sep 2023 to Sep 2024